Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.

By Zhengming Chen, H. Pan, Yiping Chen, R. Peto, R. Collins, Lixin Jiang, J. Xie, Lisheng Liu, Commit. The Lancet, 2005

878 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Emergency Medicine, Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/7e88dcfdac8aec4af8f8eea39451931980734238

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. J. Halperin
2. Hani Jneid
3. Judith Hochman
4. Allan S. Jaffe
5. M. Creager
6. C. Yancy

In Emergency Medicine

1. Allan S. Jaffe

In Endocrinology, Diabetes and Metabolism

1. M. Creager

Citations in the corpus

• 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, background): “Chen, 2005 16271643 (100) Effect of adding BB to current std therapies in AMI Multicenter randomized PC controlled 45,852 Metoprolol 22,929 PC 22,923 <24 h of ACS with STEMI, NSTEMI, or LBBB Scheduled for PCI, hypotension, bradycardia, heart block, shock IV then po, BB, or PC for up to 4 wk Death/re”
• Growing Epidemic of Coronary Heart Disease in Low- and Middle-Income Countries (2010, background): “Early use of IV metoprolol showed no overall benefit due to mixed effects on shock and coronary events early and late in the course [20].”
• 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (2008, background): “; Chen ZM et al.(4); ASSENT-4 PCI(5); Antman EM et al.”
• 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, background): “Administration of intravenous beta blockers is potentially harmful in patients with NSTE-ACS who have risk factors for shock (123).”
• ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. (2012, neutral): “was associated with an early hazard and increased mortality in the large COMMIT trial.(266) Thus, early i.”